和黄医药今日披露，其合作伙伴益普生已主动决定在美国市场撤回抗癌药物Tazverik的上市许可。这一商业决策将影响该药物在美国的后续销售与推广策略。
作为Tazverik的研发方之一，和黄医药将持续关注此次撤回对全球市场布局的潜在影响，并评估相关合作条款的调整空间。公司表示将积极配合益普生完成后续流程，同时继续推进其他创新肿瘤药物的研发进程。
和黄医药今日披露，其合作伙伴益普生已主动决定在美国市场撤回抗癌药物Tazverik的上市许可。这一商业决策将影响该药物在美国的后续销售与推广策略。
作为Tazverik的研发方之一，和黄医药将持续关注此次撤回对全球市场布局的潜在影响，并评估相关合作条款的调整空间。公司表示将积极配合益普生完成后续流程，同时继续推进其他创新肿瘤药物的研发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.